Prestige Consumer Healthcare Inc. (PBH) exhibits 54.7% gross margins and 13.8% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 7.0x enterprise multiple and 4.8% implied options volatility.
Sustained 54.7% gross profitability converts into 28.4% operating margin and 13.8% ROIC, outpacing sector cost of capital.
ROIC: 13.8% // GM: 54.7%YoY revenue trajectory of -4.3% paired with 10.67% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -4.3% // FCF YLD: 10.67%Altman Z-Score of 2.21 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.21 // F-SCORE: 6/9Trading at 12.1x trailing P/E (11.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 12.1x // EV/EBITDA: 7.0xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $48.75 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 17.5% net margins.
NET MARGIN: 17.5% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for PBH & activate live FRED threshold breach alerts.